Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO

BACKGROUND: Anti-GD2 therapy with dinutuximab is effective in improving the survival of high-risk neuroblastoma patients in remission and after relapse. However, allodynia is the major dose-limiting side effect, hindering its use for neuroblastoma patients at higher doses and for other GD2-expressin...

Descripción completa

Detalles Bibliográficos
Autores principales: Diccianni, Mitchell B., Kempińska, Katarzyna, Gangoti, Jon A., Yu, Alice L., Sorkin, Linda S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375533/
https://www.ncbi.nlm.nih.gov/pubmed/32697811
http://dx.doi.org/10.1371/journal.pone.0236115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375533/
https://www.ncbi.nlm.nih.gov/pubmed/32697811
http://dx.doi.org/10.1371/journal.pone.0236115

Ejemplares similares